Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

The criteria for diagnosing SAD are similar to diagnosing major ... disorders. On average, SAD will last about five months of ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Repetitive transcranial magnetic stimulation offers rapid depression relief for patients unresponsive to conventional ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

A new study has demonstrated the potential impact of psilocybin-assisted therapy on people with depression, if approved by ...